Imugene (Australia) Insiders
| IMU Stock | 0.04 0 5.41% |
Imugene employs about 12 people. The company is managed by 12 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive. Breaking down Imugene's management performance can provide insight into the firm performance.
| BA ASiA Chairman Executive Chairman |
Imugene |
Imugene Management Team Effectiveness
The company has return on total asset (ROA) of (0.5088) % which means that it has lost $0.5088 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9723) %, meaning that it generated substantial loss on money invested by shareholders. Imugene's management efficiency ratios could be used to measure how well Imugene manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Imugene's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 159 M in 2024, despite the fact that Change To Liabilities is likely to grow to (1.5 M).Common Stock Shares Outstanding is likely to gain to about 7.4 B in 2024, despite the fact that Net Loss is likely to grow to (32.4 M).
Imugene Workforce Comparison
Imugene is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 32,126. Imugene adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Imugene Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Imugene Price Series Summation is a cross summation of Imugene price series and its benchmark/peer.
Imugene Notable Stakeholders
An Imugene stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Imugene often face trade-offs trying to please all of them. Imugene's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Imugene's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| BA ASiA | Executive Chairman | Profile | |
| Leslie Chong | MD CEO | Profile | |
| Ursula McCurry | Senior Operations | Profile | |
| MD Woodard | Chief Officer | Profile | |
| John Byon | Senior Development | Profile | |
| Bradley Glover | Chief Officer | Profile | |
| Bradley MBA | Chief Officer | Profile | |
| Giovanni Selvaggi | Chief Officer | Profile | |
| Nathan CA | Joint Sec | Profile | |
| PharmD MBA | Chief Officer | Profile | |
| ACA BSc | Chief Officer | Profile | |
| Dr BSc | Head Development | Profile |
About Imugene Management Performance
The success or failure of an entity such as Imugene often depends on how effective the management is. Imugene management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Imugene management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Imugene management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Imugene is entity of Australia. It is traded as Stock on AU exchange.
Please note, the imprecision that can be found in Imugene's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Imugene. Check Imugene's Beneish M Score to see the likelihood of Imugene's management manipulating its earnings.
Imugene Workforce Analysis
Traditionally, organizations such as Imugene use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Imugene within its industry.Imugene Manpower Efficiency
Return on Imugene Manpower
| Revenue Per Employee | 414.2K | |
| Revenue Per Executive | 414.2K | |
| Net Loss Per Employee | 12.5M | |
| Net Loss Per Executive | 12.5M | |
| Working Capital Per Employee | 7M | |
| Working Capital Per Executive | 7M |
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.